# A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)

Study · id `cardio:ct-nct02145468` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02145468](<https://clinicaltrials.gov/study/NCT02145468>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02145468

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3503 participants.

## Technical summary

Registry record NCT02145468. Randomized; double masking; primary purpose treatment. Start 2014-06-03 (actual); primary completion 2015-12-14 (actual). Results posted on 2017-06-02.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 3503 participants (enrolled count; ClinicalTrials.gov record NCT02145468, source copy `cardio:ctgov-nct02145468-2017-06-02`, retrieved 2026-10-26)
- Started: 2014-06-03 (actual) (ClinicalTrials.gov record NCT02145468, source copy `cardio:ctgov-nct02145468-2017-06-02`, retrieved 2026-10-26)
- Primary completion: 2015-12-14 (actual) (ClinicalTrials.gov record NCT02145468, source copy `cardio:ctgov-nct02145468-2017-06-02`, retrieved 2026-10-26)
- Completion: 2015-12-14 (actual) (ClinicalTrials.gov record NCT02145468, source copy `cardio:ctgov-nct02145468-2017-06-02`, retrieved 2026-10-26)
- Results first posted: 2017-06-02 (ClinicalTrials.gov record NCT02145468, source copy `cardio:ctgov-nct02145468-2017-06-02`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Belgium; Bulgaria; Canada; Chile; Czechia; Denmark; Estonia; France; Germany; Greece; Hong Kong SAR China; Hungary; Israel; Italy; Mexico; Netherlands; New Zealand; Norway; Philippines; Poland; Romania; Russia; Slovakia; South Africa; South Korea; Spain; Sweden; Taiwan; Thailand; Ukraine; United Kingdom (ClinicalTrials.gov record NCT02145468, source copy `cardio:ctgov-nct02145468-2017-06-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02145468-2017-06-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)
- Acronym: LATITUDE
- Condition: Acute Coronary Syndrome
- Intervention (Drug): Losmapimod 7.5 mg twice daily
- Intervention (Drug): Placebo twice daily
- Intervention (Drug): Standard therapy
- Lead sponsor: GlaxoSmithKline
- Lead sponsor class: INDUSTRY
- Collaborator: The TIMI Study Group
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Non-ST-elevation heart attack (NSTEMI) (`cardio:nstemi`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry lists this organization as the lead sponsor: GlaxoSmithKline (`cardio:org-glaxosmithkline`)
- Registry lists this organization as a collaborator: The TIMI Study Group (`cardio:org-the-timi-study-group`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial (`cardio:pubmed-27043082`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 015679438d4f6437ebab028f1dd90129fb41c3bfec8bae1c512fed129da0d8d6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
